A recent survey revealed that over 72% of US adults aged 50 and older would consider a cost-effective vaccine that could reduce dementia risk by half. Despite its potential benefits, 28% would refuse the vaccine, indicating a significant level of… Read More »The majority of US adults are willing to receive a dementia vaccine
New research suggests the century-old BCG tuberculosis vaccine may also reduce Alzheimer’s disease risk. Originally developed against TB by Calmette and Guérin and proven highly effective, this vaccine now appears to have broad immunotherapeutic benefits. Clinical trials have demonstrated its… Read More »BCG vaccine may be a weapon against Alzheimer’s disease
New results from a phase 2A clinical trial show that the new Alzheimer’s disease vaccine from Vaxxinity has promising results.
This article discusses the list of vaccine candidates, along with clinical trials, for Alzheimer’s disease in 2023.
The pharmaceutical company AC Immune SA has received FDA clearance to proceed with phase 1 and 2 clinical trials for its anti-amyloid beta vaccine for the treatment of Alzheimer’s disease. If the results of the clinical trial are positive, this… Read More »Alzheimer’s disease vaccine beginning clinical trials